Proparacaine

Generic Name: Proparacaine

Brand Names: Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₆N_₂O_₃

CAS Number: 499-67-2

Unique Ingredient Identifier: B4OB0JHI1X

Background: Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.

Indication: Used as a local (ophthalmic) anesthetic.

Associated Conditions: Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Associated Therapies: Local Anaesthesia therapy

Clinical Trials

Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

Phase 3

Active, not recruiting

Conditions: Light Chain Deposition Disease
Smoldering Multiple Myeloma

Interventions: Drug: Lenalidomide
Other: Clinical Observation
Other: Quality-of-Life Assessment

First Posted Date: 2010-07-26

Last Posted Date: 2024-11-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 226

Registration Number: NCT01169337

Locations: 🇺🇸
Illinois CancerCare-Carthage, Carthage, Illinois, United States
🇺🇸
Memorial Hospital, Carthage, Illinois, United States
🇺🇸
Centralia Oncology Clinic, Centralia, Illinois, United States

and more 606 locations

A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma

Phase 1

Completed

Conditions: Adult T-cell Leukemia-Lymphoma
Peripheral T-cell Lymphoma

Interventions: Drug: Lenalidomide

First Posted Date: 2010-07-26

Last Posted Date: 2019-11-08

Lead Sponsor: Celgene

Target Recruit Count: 13

Registration Number: NCT01169298

Locations: 🇯🇵
Imamura Bun-in Hospital, Kagoshima, Japan
🇯🇵
Nagoya Daini Red Cross Hospital, Nagoya, Japan
🇯🇵
Kumamoto University Hospital, Kumamoto, Japan

and more 3 locations

Lenalidomide and Cetuximab in Patients With Advanced Solid Tumors

Phase 1

Conditions: Solid Tumors

First Posted Date: 2010-07-20

Last Posted Date: 2010-07-20

Lead Sponsor: Medical University Innsbruck

Target Recruit Count: 20

Registration Number: NCT01166035

Locations: 🇦🇹
Medical University of Innsbruck, Department for Internal Medicine I, Innsbruck, Tyrol, Austria

Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma

Phase 1

Completed

Conditions: Refractory Multiple Myeloma

Interventions: Drug: azacitidine
Drug: lenalidomide
Drug: dexamethasone
Other: DNA methylation analysis
Other: gene expression analysis
Other: bone marrow aspiration
Other: immunohistochemistry staining method
Other: reverse transcriptase-polymerase chain reaction
Other: flow cytometry

First Posted Date: 2010-07-02

Last Posted Date: 2020-11-16

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 45

Registration Number: NCT01155583

Locations: 🇺🇸
University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Lenalidomide and Rituximab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma

Phase 2

Completed

Conditions: Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma
Ann Arbor Stage III Grade 1 Follicular Lymphoma
Ann Arbor Stage IV Grade 2 Follicular Lymphoma
Ann Arbor Stage IV Grade 3 Follicular Lymphoma
Ann Arbor Stage IV Grade 1 Follicular Lymphoma
Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma
Ann Arbor Stage II Grade 2 Non-Contiguous Follicular Lymphoma
Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma
Ann Arbor Stage III Grade 3 Follicular Lymphoma
Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma

Interventions: Other: Laboratory Biomarker Analysis
Drug: Lenalidomide
Biological: Rituximab

First Posted Date: 2010-06-16

Last Posted Date: 2023-06-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 66

Registration Number: NCT01145495

Locations: 🇺🇸
Memorial Hospital, Carthage, Illinois, United States
🇺🇸
Illinois CancerCare-Havana, Havana, Illinois, United States
🇺🇸
Heartland Cancer Research NCORP, Decatur, Illinois, United States

and more 88 locations

Lenalidomide and Prednisone in Low and Int-1 Myelodysplastic Syndrome (MDS) Non 5q MDS

Phase 2

Completed

Conditions: Myelodysplastic Syndrome
MDS

Interventions: Drug: Prednisone
Drug: Lenalidomide

First Posted Date: 2010-05-28

Last Posted Date: 2019-12-17

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 28

Registration Number: NCT01133275

Locations: 🇺🇸
University of Florida Shands Cancer Center, Gainesville, Florida, United States
🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA
Secondary Myelodysplastic Syndrome
Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11
de Novo Myelodysplastic Syndrome
Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL
Alkylating Agent-Related Acute Myeloid Leukemia
Previously Treated Myelodysplastic Syndrome
Recurrent Adult Acute Myeloid Leukemia

Interventions: Drug: Lenalidomide
Drug: Cytarabine
Drug: Idarubicin
Other: Pharmacological Study
Other: Laboratory Biomarker Analysis

First Posted Date: 2010-05-28

Last Posted Date: 2014-12-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 61

Registration Number: NCT01132586

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma

Phase 2

Conditions: Cutaneous T Cell Lymphoma

First Posted Date: 2010-05-28

Last Posted Date: 2010-05-28

Lead Sponsor: Florida Academic Dermatology Centers

Target Recruit Count: 10

Registration Number: NCT01132989

Locations: 🇺🇸
Florida Academic Dermatology Center, Miami, Florida, United States

RESPeCT: Revlimid Early Stage Poor Prognosis Chronic Lymphocytic Leukaemia (CLL) Trial

Phase 2

Terminated

Conditions: Chronic Lymphocytic Leukaemia

Interventions: Drug: Lenalidomide

First Posted Date: 2010-05-21

Last Posted Date: 2011-12-05

Lead Sponsor: The Christie NHS Foundation Trust

Target Recruit Count: 1

Registration Number: NCT01127542

Locations: 🇬🇧
The Royal Bournemouth Hospital, Bournemouth, Dorset, United Kingdom
🇬🇧
St James's University Hospital, Leeds, United Kingdom
🇬🇧
Addenbrooke's Hospital, Cambridge, United Kingdom

and more 6 locations

Lenalidomide for Lean Body Mass and Muscle Strength in Inflammatory Cancer Cachexia Syndrome

Phase 1

Completed

Conditions: Cancer Cachexia Syndrome

Interventions: Other: basic cachexia management (prokinetics, physical activity counselling, nutritional counselling)
Drug: Lenalidomide

First Posted Date: 2010-05-20

Last Posted Date: 2017-08-01

Lead Sponsor: Florian Strasser, MD ABHPM

Target Recruit Count: 200

Registration Number: NCT01127386

Locations: 🇨🇭
Kantonsspital St.Gallen, St.Gallen, Switzerland

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy